News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
284,294 Results
Type
Article (15398)
Company Profile (299)
Press Release (268591)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (80272)
Career Advice (185)
Deals (13428)
Drug Delivery (39)
Drug Development (50841)
Employer Resources (31)
FDA (5861)
Job Trends (5246)
News (145874)
Policy (10243)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (932)
Accelerated approval (19)
Adcomms (14)
Allergies (85)
Alliances (21881)
ALS (126)
Alzheimer's disease (1038)
Antibody-drug conjugate (ADC) (244)
Approvals (6058)
Artificial intelligence (268)
Autoimmune disease (119)
Automation (9)
Bankruptcy (109)
Best Places to Work (4589)
BIOSECURE Act (7)
Biosimilars (101)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (46)
Breast cancer (352)
Cancer (3173)
Cardiovascular disease (241)
Career advice (169)
Career pathing (9)
CAR-T (225)
CDC (5)
Cell therapy (578)
Cervical cancer (14)
Clinical research (43815)
Collaboration (1168)
Company closure (2)
Compensation (603)
Complete response letters (41)
COVID-19 (1114)
CRISPR (88)
C-suite (568)
Cystic fibrosis (113)
Data (4364)
Denatured (15)
Depression (93)
Diabetes (257)
Diagnostics (1397)
Digital health (13)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (198)
Drug pricing (49)
Drug shortages (3)
Duchenne muscular dystrophy (218)
Earnings (31747)
Editorial (29)
Employer branding (4)
Employer resources (30)
Events (51906)
Executive appointments (629)
FDA (7633)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (998)
Gene editing (185)
Generative AI (22)
Gene therapy (498)
GLP-1 (512)
Government (1198)
Grass and pollen (3)
Guidances (166)
Healthcare (6685)
HIV (18)
Huntington's disease (43)
IgA nephropathy (75)
Immunology and inflammation (195)
Immuno-oncology (44)
Indications (71)
Infectious disease (1224)
Inflammatory bowel disease (157)
Inflation Reduction Act (11)
Influenza (40)
Intellectual property (169)
Interviews (18)
IPO (7371)
IRA (13)
Job creations (914)
Job search strategy (147)
JPM (41)
Kidney cancer (9)
Labor market (25)
Layoffs (250)
Leadership (10)
Legal (1453)
Liver cancer (41)
Longevity (11)
Lung cancer (426)
Lymphoma (251)
Machine learning (24)
Management (7)
Manufacturing (384)
MASH (132)
Medical device (2715)
Medtech (2724)
Mergers & acquisitions (6688)
Metabolic disorders (739)
Multiple sclerosis (105)
NASH (13)
Neurodegenerative disease (233)
Neuropsychiatric disorders (71)
Neuroscience (1970)
Neurotech (1)
NextGen: Class of 2026 (2068)
Non-profit (914)
Now hiring (31)
Obesity (337)
Opinion (129)
Ovarian cancer (133)
Pain (103)
Pancreatic cancer (166)
Parkinson's disease (232)
Partnered (12)
Patents (307)
Patient recruitment (345)
Peanut (44)
People (26809)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15518)
Phase 2 (20360)
Phase 3 (12860)
Pipeline (3357)
Policy (95)
Postmarket research (857)
Preclinical (6559)
Press Release (30)
Prostate cancer (147)
Psychedelics (50)
Radiopharmaceuticals (240)
Rare diseases (665)
Real estate (1514)
Recruiting (13)
Regulatory (10016)
Reports (20)
Research institute (1002)
Resumes & cover letters (23)
Rett syndrome (24)
RNA editing (21)
RSV (17)
Schizophrenia (125)
Series A (184)
Series B (141)
Service/supplier (1)
Sickle cell disease (78)
Special edition (18)
Spinal muscular atrophy (120)
Sponsored (15)
Startups (2029)
State (1)
Stomach cancer (5)
Supply chain (33)
Tariffs (20)
The Weekly (62)
Vaccines (343)
Venture capital (71)
Weight loss (178)
Women's health (26)
Worklife (2)
Date
Last 7 days (318)
Last 30 days (1117)
Last 365 days (17790)
2026 (1971)
2025 (18135)
2024 (20601)
2023 (22485)
2022 (27061)
2021 (28166)
2020 (23572)
2019 (16402)
2018 (11902)
2017 (13883)
2016 (11970)
2015 (14472)
2014 (10485)
2013 (7563)
2012 (7632)
2011 (7721)
2010 (7504)
Location
Africa (166)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18527)
Australia (3135)
California (7153)
Canada (1861)
China (787)
Colorado (249)
Connecticut (256)
Delaware (237)
Europe (39434)
Florida (914)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (400)
India (36)
Indiana (164)
Iowa (9)
Japan (228)
Kansas (83)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (745)
Massachusetts (5634)
Michigan (111)
Minnesota (251)
Mississippi (3)
Missouri (33)
Montana (16)
Nebraska (6)
Nevada (33)
New Hampshire (21)
New Jersey (1662)
New Mexico (13)
New York (1780)
North Carolina (838)
North Dakota (6)
Northern California (3520)
Ohio (181)
Oklahoma (11)
Oregon (24)
Pennsylvania (1288)
Puerto Rico (9)
Rhode Island (27)
South America (226)
South Carolina (9)
Southern California (2839)
Tennessee (40)
Texas (922)
United States (23576)
Utah (97)
Virginia (139)
Washington D.C. (38)
Washington State (595)
West Virginia (1)
Wisconsin (47)
284,294 Results for "spur therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Spur Therapeutics Presents New Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at 22nd Annual WORLDSymposium™
February 4, 2026
·
4 min read
Alzheimer’s disease
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
February 9, 2026
·
4 min read
·
Annalee Armstrong
Autoimmune disease
Cabaletta’s CAR T Therapy Spurs Remissions in Small Lupus Trial
Phase I/II data for rese-cel point to its therapeutic potential in systemic lupus erythematosus and lupus nephritis, as well as other autoimmune conditions.
October 28, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Spur Therapeutics to Present New Clinical Data on Its Gene Therapy Candidate in Gaucher Disease at Upcoming ESGCT Annual Congress
October 1, 2025
·
1 min read
Press Releases
Spur® Elute DEEPER CORONARY Study Completes Enrollment
September 29, 2025
·
3 min read
Press Releases
Spur Therapeutics Presents Updated Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at ESGCT 32nd Annual Congress
October 7, 2025
·
3 min read
Press Releases
Spur Therapeutics to Participate in Citizens JMP 2025 Life Sciences Conference
May 2, 2025
·
1 min read
Spur Therapeutics (Formerly Freeline) Announces New Name and Brand
Spur Therapeutics, formerly Freeline Therapeutics, today announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine.
June 17, 2024
·
5 min read
Press Releases
Spur Therapeutics Presents Positive New Clinical and Preclinical Data on Its Gene Therapy Programs at ASGCT 28th Annual Meeting
May 15, 2025
·
4 min read
Spur Therapeutics to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Spur Therapeutics, formerly Freeline Therapeutics, today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference being held on June 27th, 2024.
June 20, 2024
·
1 min read
1 of 28,430
Next
